RetinaCME
EXPERT VIDEOCME

RetinaCME® Presents Updates from Vancouver: Best of Ophthalmology Research on Improving Outcomes With New Treatment Options for Neovascular Retinal Diseases

Author(s)/Faculty: Rishi P. Singh, MD; Karl G. Csaky, MD, PhD; Veeral Sheth, MD, MBA
Release Date: 5/9/2019Expiration Date: 5/8/2020
Credit Type: CMENumber of Credits: 0.75
Content Type: VideoProvider:
The integration of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy into algorithms for the treatment of neovascular retinal disease has revolutionized outcomes in patients with the disease. However, individualizing dosing schedules to maintain visual acuity gains can be challenging and burdensome on the patient. In addition, clinical studies have demonstrated that approximately two-thirds of treated patients have a suboptimal response to anti-VEGF therapy, indicating a need for the identification of new molecular targets for therapeutic intervention. In this educational activity, recorded during the spring meeting in Vancouver, British Columbia, experts in the field review the current evidence regarding the long-term effectiveness of treatments for patients with neovascular retinal disease and evaluate the latest data on emerging therapies that may improve outcomes for these patients.